

FAIRVIEW ADVISORS COMPLETES SALE OF INTELLECTUAL PROPERTY FOR LEADING BIOMEDICAL VENTURE CAPITALISTS

Naples, Florida and San Francisco, California, November, 2005 — Fairview Advisors, LLC, an investment banking firm led by seasoned executives, completed the sale of a substantial portion of the intellectual property for Genteric, Inc., a seed stage developer of therapeutic protein drugs, to Altor BioScience Corporation in exchange for stock.

Sanderling, and several other leading biotech and healthcare venture capitalists, engaged FairView to sell Genteric, Inc., one of their portfolio companies, and/or its intellectual property. The company's novel approach to therapeutic protein delivery, although promising, was still several years away from commercial development.

Fairview identified several potential buyers of the technology but selected Altor as the buyer that would likely represent the best fit with Sanderling's objectives. Fairview was successful in structuring a multifaceted transaction that would serve Sanderling, Altor and Genteric.

"This was a complicated and time consuming transaction involving several different moving parts including the sale of the IP, a large patent portfolio, and re-negotiation of necessary licenses from several leading Universities," said Dr. Mitchell Finer, CEO of Intracel Holdings Corporation and former CEO of Genteric, Inc. "It took the better part of a year to close this transaction and Fairview's tenacity and hard work ultimately prevailed in successfully concluding the sale." According to FairView Advisors', John Taylor, "We are pleased to help Genteric's shareholders with this transaction and look forward to continuing to work in the biomedical marketplace."

About FairView Advisors

FairView Advisors specializes in Mergers and Acquisitions, debt and private equity financing as well as strategic advisory work for companies in select industries, including, biomedical and healthcare, financial services, information technology, telecom and wireless as well as sports and media. Led by a seasoned management team with significant financial and operating experience, FairView Advisors utilizes a team approach to assist its clients in defining their issues and needs, and then executing a transaction to achieve the client's desired results. The company's senior management team has completed numerous transactions in their targeted industries including M&A, capital raising, and strategic advisory work and has individually grown firms to multi-billion market capitalizations. The company is headquartered in Naples, Florida and maintains offices in New Jersey and Northern California. The company's website is www.fairviewadvisors.com.

About Sanderling and Genteric

Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling's unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates-of-return for both its entrepreneurs and investors. Since its inception, Sanderling has supported over 40 biomedical companies from very early stages through commercial development, earning consistently high rates-of-return on its venture investments. For more information about Sanderling, visit their website at www.sanderling.com.

Genteric was formed to commercialize revolutionary therapeutic protein gene delivery technologies. The Company's mission was to become the market leader in therapeutic protein delivery—a multi-billion market opportunity.

About Altor BioScience Corporation

Altor BioScience Corporation is a biopharmaceutical company developing a new class of therapeutic products for the treatment of cancer, viral infections and autoimmune diseases. Altor was launched in August 2002 as a spin-off of Sunol Molecular Corporation. With extensive experience in the biotechnology industry, Altor's scientific and management team has the knowledge required to take products from concept to clinical testing. Several of Altor's product candidates are already in the advanced stages of testing necessary to initiate human clinical trials. For more information about Altor, visit their website at www.altorbioscience.com.